Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04712851 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Final enrollment: 18 participants (planned 25)
    • Eligibility criteria expanded, about 35 words
    • Site details revised
    • Collaborators: details revised at 1 of 1 entry
  2. Re-verified, no change to tracked fieldsv12
  3. Primary completion date: Jan 31, 2026 to Jan 31, 2027
    • Study completion date: Jan 31, 2027 to Jan 31, 2028
    v11
  4. Primary completion date: Jan 31, 2025 to Jan 31, 2026
    • Study completion date: Jan 31, 2026 to Jan 31, 2027
    v10
  5. Primary completion date: Jan 31, 2024 to Jan 31, 2025
    • Study completion date: Jan 31, 2025 to Jan 31, 2026
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Primary completion date: Jan 31, 2023 to Jan 31, 2024
    • Study completion date: Jan 31, 2024 to Jan 31, 2025
    v8
  2. Re-verified, no change to tracked fieldsv7
  3. Site contact updated
    • Study description expanded, about 5 words
    v6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2021 to Jun 30, 2021
    • Site details revised
    v5
  5. Primary endpoint revisedv4 Show 6 more changesShow less
    • Start date: Jun 30, 2021 to Jul 1, 2021
    • Eligibility criteria shortened, about 275 words
    • Secondary endpoints: 4 to 2
    • Study description shortened, about 94 words
    • Study site revised
    • Study title shortened, about 4 words
  6. Start date: Apr 30, 2021 to Jun 30, 2021v3
  7. Start date: Jan 31, 2021 to Apr 30, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Trial Details
NCT Number NCT04712851
Lead Sponsor Jonsson Comprehensive Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2
Related terms Uterine Cervical Dysplasia
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov